Opportunistic and chronic infections may be rare and are often difficult to diagnose, especially in patients with autoimmune inflammatory rheumatic diseases (AIIRD), that may be immunocompromised.

A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG).

Researchers from Harvard have reported their analysis showing that the large increase in colchicine cost in 2010 was associated with an immediate decrease in colchicine prescription use, with a 10 year increase in emergency department and rheumatology gout visits suggesting poorer gout control.

New research highlights potential safety concerns around women taking romosozumab, a new anti-osteoporosis drug available on the NHS.

On the first day of ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. Dr. Petri, a lupus expert from Johns Hopkins Rheumatology, reviewed the latest clinical and animal model studies that offer hope in treatment and gave wide-ranging pearls on a variety of issues that can be faced in this disorder. 

Pneumocystis jirovecii pneumonia (PJP) can be a life-threatening infection in immunocompromised patients. The 2023 EULAR Vasculitis guidelines recommends primary prophylaxis with antibiotics, especially in rheumatic disease patients receiving rituximab (RTX).

Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.

The British Medical Journal has publish a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of incident type 2 diabetes (NIDDM) compared with those taking oral bisphosphonates for osteoporosis.

Two independent data sets suggests the prevalence of gout among Asians has grown such that this sub-population has numerically surpassed all other racial and ethnic groups by 2018.